{"layout":"Indicator","sdg_goal":"3","goal_number":"3","indicator_number":"3.b.3","indicator_sort_order":"03-bb-03","permalink":"/3-b-3/","reporting_status":"notstarted","published":true,"data_non_statistical":false,"national_indicator_available":null,"comparison_sdg":null,"goal_meta_national_link":null,"goal_meta_national_link_text":"National metadata","indicator_name":"Proportion of health facilities that have a core set of relevant essential medicines available and affordable on a sustainable basis","target_name":"Forschung und Entwicklung zu Impfstoffen und Medikamenten f\u00fcr \u00fcbertragbare und nicht\u00fcbertragbare Krankheiten, von denen haupts\u00e4chlich Entwicklungsl\u00e4nder betroffen sind, unterst\u00fctzen, den Zugang zu bezahlbaren unentbehrlichen Arzneimitteln und Impfstoffen gew\u00e4hrleisten, im Einklang mit der Erkl\u00e4rung von Doha \u00fcber das TRIPS-\u00dcbereinkommen und die \u00f6ffentliche Gesundheit, die das Recht der Entwicklungsl\u00e4nder bekr\u00e4ftigt, die Bestimmungen in dem \u00dcbereinkommen \u00fcber handelsbezogene Aspekte der Rechte des geistigen Eigentums \u00fcber Flexibilit\u00e4ten zum Schutz der \u00f6ffentlichen Gesundheit voll auszusch\u00f6pfen, und insbesondere den Zugang zu Medikamenten f\u00fcr alle zu gew\u00e4hrleisten","target_id":"3.b","un_designated_tier":"<a href=\"https://unstats.un.org/sdgs/iaeg-sdgs/tier-classification/\" title=\"Click here for more information on the UN tier classification.\">Tier II</a>","un_custodian_agency":"World Health Organization (WHO)","goal_meta_link":"https://unstats.un.org/sdgs/metadata/files/Metadata-03-0B-03.pdf","goal_meta_link_text":"United Nations Sustainable Development Goals Metadata","source_active_1":false,"source_active_2":false,"source_active_3":false,"source_active_4":false,"source_active_5":false,"source_active_6":false,"data_keywords":null,"data_show_map":false,"data_start_values":null,"computation_units":null,"copyright":"&copy; Federal Statistical Office (Destatis), 2020","data_footnote":null,"graph_title":null,"graph_type":"line","graph_min_value":null,"graph_max_value":null,"previous":"3-b-2","next":"3-c-1","national_geographical_coverage":"Germany","national_data_update_url_text":"2018-09-25: see changes on GitHub","national_data_update_url":"https://github.com/G205SDGs/sdg-data/commit/2d635295bda496256a73e337c6f647e9de44d95d","national_metadata_update_url_text":"2020-07-15: see changes on GitHub","national_metadata_update_url":"https://github.com/G205SDGs/sdg-data/commit/bae7b185b9c4cbce6ce882204a80126658103af2","page_content":"\n<span class=\"status notstarted\"> Exploring data sources </span><br>\nSuitable data sources for this indicator are currently being explored.\nThis indicator is classified as Tier 3 and therefore no internationally established methodology or statistical standards are yet available. Corresponding methodologies or standards are being developed by the responsible international organizations and subsequently tested in cooperation with national statistical offices.\n\nIf you have any feedback or suggestions on data please contact us through the contact form below.","indicator":"3.b.3","language":"en","target":"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","goal_meta_2_link_text":null,"goal_meta_3_link_text":null}